Outcomes of De Novo Allograft Diabetic Nephropathy in Renal Allograft Recipients

Abstract

Objectives: Despite increased use of diabetogenic immunosuppressive drugs and increased incidence of new-onset diabetes after transplant in renal allograft recipients, there are few case studies on the subject of de novo allograft diabetic nephropathy and interstitial fibrosis/tubular atrophy without specific glomerular changes. We sought to study the outcomes of allograft diabetic nephropathy and interstitial fibrosis/tubular atrophy without specific glomerular changes in patients with new-onset diabetes after transplant. Conclusions:De novo allograft diabetic nephropathy is a significant cause of graft and patient loss in renal allograft recipients who develop new-onset diabetes after transplant.

Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome‑mediated IL‑1β secretion via c‑Jun N‑terminal kinase activation and cell apoptosis during diabetic nephropathy

“…Diabetic nephropathy (DN) is a serious complication of diabetes and may result in end-stage renal failure ( 1 , 2 ). In total, ~30% of patients with diabetes mellitus (DM) developed DN following a disease duration of 15–30 years ( 3 , 4 ). The morbidity of DN is markedly rising with the increasing incidence and prevalence of diabetes.…”

The Role of Ubiquitination and Sumoylation in Diabetic Nephropathy

“…About 30–40% of patients with type 1 diabetes (T1DM) and 20–30% of patients with type 2 diabetes (T2DM) would develop DN after the disease duration of 15–30 years [1, 2]. The morbidity of DN is rising year by year with the increasing incidence and prevalence of diabetes dramatically and disproportionately, and the pathogenesis of DN has not been completely clarified; its treatment is limited, unsatisfactory, and expensive [3]. DN patients always have a poor prognosis which is a leading cause of end-stage renal disease and a contributor to significant morbidity and mortality in patients with diabetes [4].…”